Oxford Genetics Ltd

Activities: Research & Development Microbiology

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Automated microfluidics for gene editing is in the works

Oxford Genetics has announced a partnership to optimise the way laboratories deliver gene editing to cells and interrogate the resultant products

Oxford Genetics appoints new Chief Operating Officer Jocelyne Bath
Analysis

CRISPR gene editing technology licence extended

Oxford Genetics has extended its CRISPR gene editing technology licence agreement from ERS Genomics to support its international growth
Analysis

Oxford Genetics to deliver custom CRISPR mammalian cell lines

The synthetic biology company signs major supply and licensing agreement
Digital

Oxford Genetics announces new online customer portal

This new portal, according to Oxford Genetics will provide customers with real-time updates through 24/7 access to the status of the projects
Regulatory

Adeno-associated virus vectors research collaboration

Oxford Genetics, a leader in innovative synthetic biology based technologies for biologics discovery, development and delivery, has established a new agreement with clinical-stage gene therapy company, MeiraGTx
Media

Oxford Genetics licenses SnapFast expression vectors to Twist Bioscience

Oxford Genetics will supply Twist Bioscience with its SnapFast technology platform to provide a broad range of application-specific expression vectors, which Twist Bioscience will use to clone synthesised DNA for its diverse customer base
Subscribe now